Evidence map›Paper›PMID 33306117›Full record

ArticleJAMA network open2020

Parent-Reported Symptoms and Medications Used Among Children With Severe Neurological Impairment.

James A Feinstein, Chris Feudtner, Allison B Blackmer, Robert J Valuck, Diane L Fairclough, Jacqueline Holstein, LiseAnne Gregoire, Sadaf Samay, Allison Kempe

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in JAMA network open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03849066 completednot on this map

Enhancing Medication Safety in Children With Polypharmacy Using Parent- Reported Symptom Assessments

TypeobservationalSponsorUniversity of Colorado, DenverRan2019 to 2022Enrolled136ConditionsNeurologic Disorder, Chronic Disease, Pediatric DisorderArmsParent-Reported Symptom Assessment
NCT05761847 narecruitingnot on this mapstarted 2023, after this paper: background citation

Optimizing the Clinical Management of Polypharmacy for Children With Medical Complexity: The Pediatric Medication Therapy Management (pMTM) Trial

TypeinterventionalSponsorUniversity of Colorado, DenverRan2023 to 2028Enrolled371ConditionsChild, Only, Disabilities Multiple, Medication Interaction, Medication ComplianceArmsPediatric Medication Therapy Management (pMTM)
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

James A FeinsteinAdult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado and Children's Hospital Colorado, Aurora.
Chris FeudtnerDivision of General Pediatrics, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Allison B BlackmerSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora.
Robert J ValuckSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora.
Diane L FaircloughAdult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado and Children's Hospital Colorado, Aurora.
Jacqueline HolsteinResearch Institute, Children's Hospital Colorado, Aurora.
LiseAnne GregoireResearch Institute, Children's Hospital Colorado, Aurora.
Sadaf SamayResearch Informatics, Analytics Resource Center, Children's Hospital Colorado, Aurora.
Allison KempeAdult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado and Children's Hospital Colorado, Aurora.
Children's Hospital Colorado · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · USChildren's Hospital of Philadelphia · US

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025780 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$61.3M
Enhancing Medication Safety in Children with Polypharmacy Using Parent-Reported Symptom AssessmentsK23HD091295 · NICHD · UNIVERSITY OF COLORADO DENVER · PI FEINSTEIN, JAMES A · 2017 to 2021
$826k
NCRR NIH HHS UL1 RR025780NICHD NIH HHS K23 HD091295
6 · The paper itself

Abstract

Importance: Children with severe neurological impairment (SNI) often take multiple medications to treat problematic symptoms. However, for children who cannot self-report symptoms, no system exists to assess multiple symptoms and their association with medication use. Objectives: To assess the prevalence of 28 distinct symptoms, test whether higher global symptom scores (GSS) were associated with use of more medications, and assess the associations between specific symptoms and medications. Design, Setting, and Participants: This cross-sectional study was conducted between April 1, 2019, and December 31, 2019, using structured parent-reported symptom data paired with clinical and pharmacy data, at a single-center, large, hospital-based special health care needs clinic. Participants included children aged 1 to 18 years with SNI and 5 or more prescribed medications. Data analysis was performed from April to June 2020. Exposure: During routine clinical visits, parent-reported symptoms were collected using the validated 28-symptom Memorial Symptom Assessment Scale (MSAS) and merged with clinical and pharmacy data. Main Outcomes and Measures: Symptom prevalence, counts, and GSS (scored 0-100, with 100 being the worst) were calculated, and the association of GSS with medications was examined. To evaluate associations between symptom-medication pairs, the proportion of patients with a symptom who used a medication class or specific medication was calculated. Results: Of 100 patients, 55.0% were boys, the median (interquartile range [IQR]) age was 9 (5-12) years, 62.0% had 3 or more complex chronic conditions, 76.0% took 10 or more medications, and none were able to complete the MSAS themselves. Parents reported a median (IQR) of 7 (4-10) concurrent active symptoms. The median (IQR) GSS was 12.1 (5.4-20.8) (range, 0.0-41.2) and the GSS was 9.8 points (95% CI, 5.5-14.1 points) higher for those with worse recent health than usual. Irritability (65.0%), insomnia (55.0%), and pain (54.0%) were the most prevalent symptoms. Each 10-point GSS increase was associated with 12% (95% CI, 4%-19%) higher medication counts, adjusted for age and complex chronic condition count. Among the 54.0% of children with reported pain, 61.0% were prescribed an analgesic. Conclusions and Relevance: These findings suggest that children with SNI reportedly experience substantial symptom burdens and that higher symptom scores are associated with increased medication use. Paired symptom-medication data may help clinicians identify targets for personalized symptom management, including underrecognized or undertreated symptoms.

Indexed as

Medication Therapy ManagementNervous System DiseasesParentsPrescription Drug OveruseSymptom AssessmentAnalgesicsBehavioral SymptomsChildChronic DiseaseColoradoCross-Sectional StudiesData CollectionFemaleHumansMalePainAnalgesics

Identifiers

PMID33306117
PMCPMC7733159
OpenAlexW3111254090

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.